Page last updated: 2024-08-25

rosiglitazone and Breast Cancer

rosiglitazone has been researched along with Breast Cancer in 35 studies

Research

Studies (35)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	17 (48.57)	29.6817
2010's	12 (34.29)	24.3611
2020's	6 (17.14)	2.80

Authors

Authors	Studies
Cai, S; Cichewicz, RH; Doench, JG; Grant, CV; Liang, H; Mooberry, SL; O'Keefe, BR; Risinger, AL	1
Caruso, JA; Chen, YY; Chen-Tanyolac, C; Gartner, ZJ; Gascard, P; Kerlikowske, K; Murrow, LM; Rodriguez, CI; Tlsty, TD; Vu, L; Wang, X	1
Andò, S; Augimeri, G; Barone, I; Bonofiglio, D; Catalano, S; Gelsomino, L; Gionfriddo, G; Giordano, C; Giordano, F; Morelli, C; Plastina, P; Sisci, D; van Norren, K; Witkamp, R	1
Calvo, JC; Gantov, M; Lotufo, C; Pagnotta, P; Riera, MF; Rindone, GM; Toneatto, J	1
Geldenhuys, W; Pistilli, EE; Rellick, S; Stanton, DA; Wilson, HE	1
Fan, R; Li, J; Pei, W; Wang, H; Wang, X; Wang, Y; Zeng, X; Zhang, Y	1
Bantug, G; Christofori, G; Diepenbruck, M; Hess, C; Ishay-Ronen, D; Ivanek, R; Kalathur, RKR; Morini, MF; Sugiyama, N; Tiede, S; Wang, J	1
Arif, IS; Boateng, SY; Greco, F; Hooper, CL; Williams, AC	1
To, KK; Tomlinson, B	1
Dhillon, SK; Nagasaki, Y; Sakharkar, KR; Sakharkar, MK; Sharma, K; Shashni, B; Singh, R	1
Baxter, RC; Firth, SM; Pon, CK	1
Apellániz-Ruiz, M; Bergmann, TK; Brøsen, K; Green, H; Ingelman-Sundberg, M; Johansson, I; Lee, MY; Rodríguez-Antona, C; Vikingsson, S	1
Carson, DD; Morgado, M	1
Tseng, CH	1
Akiyama, TE; Alexander, RL; Berger, JP; Gorczynski, MJ; King, SB; Morrow, CS; Smitherman, PK; Wood, HB; Wright, MW	1
Andò, S; Bonofiglio, D; Catalano, S; Cione, E; Fuqua, SA; Genchi, G; Panno, ML; Perri, M; Pingitore, A; Qi, H; Vizza, D	1
Chang, MK; Clément, MV; Hewitt, RE; Kumar, AP; Lim, KS; Pervaiz, S; Quake, AL; Salto-Tellez, M; Singh, R; Zhou, T	1
Dornfeld, K; Skildum, A; Wallace, K	1
Andò, S; Bonofiglio, D; Catalano, S; Cione, E; Genchi, G; Perri, M; Pingitore, A; Qi, H; Rovito, D; Vizza, D	1
Ensor, J; Esteva, FJ; Gonzalez-Angulo, AM; Green, MC; Hortobagyi, GN; Koenig, KB; Lee, MH; Moulder, SL; Murray, JL; Yeung, SC	1
Knight, BB; Nagalingam, A; Oberlick, E; Saxena, NK; Sharma, D; Taliaferro-Smith, L	1
Elstner, E; Fenner, MH; Liu, H; Possinger, K; Zang, C	1
Burgermeister, E; Liscovitch, M; Tencer, L	1
Albanese, C; Brownlee, M; Donehower, LA; Fu, M; Harris, EL; Hulit, J; Johns, DC; Jones, JG; Li, Z; Neumeister, P; Novikoff, PM; Pattabiraman, N; Pestell, RG; Rohan, T; Sakamaki, T; Scherer, PE; Wang, C; Whitney, KD; Wu, K; Zhou, JN	1
Cocca, C; Perez-Castillo, A; Pignatelli, M; Santos, A	1
Gill, JH; Seargent, JM; Yates, EA	1
Allred, CD; Kilgore, MW	1
Andò, S; Aquila, S; Bonofiglio, D; Catalano, S; Gabriele, S; Gentile, M; Giordano, F; Middea, E	1
Chatterjee, VK; Chen, CS; Eng, C; Shaiu, CW; Teresi, RE; Waite, KA	1
Cheon, HG; Kim, KY; Kim, SS	1
Andò, S; Aquila, S; Belmonte, M; Bonofiglio, D; Catalano, S; Gabriele, S; Gentile, M; Maggiolini, M; Middea, E; Morelli, C; Qi, H	1
Eng, C; Farrar, WB; Johnson, MV; Lester, J; Povoski, SP; Suster, S; Walker, MJ; Wen, P; Williams, N; Yee, LD; Young, DC	1
Allred, CD; Kilgore, MW; Talbert, DR; Zaytseva, YY	1
Bloomston, M; Chou, FS; Dharker, N; Glickman, TS; Lee, D; McCaffrey, T; Mody, M; Pinzone, JJ; Pumfery, A; Ringel, MD; Wang, PS; Yang, Z	1
Kalus, AM; Rubin, GL; Simpson, ER; Zhao, Y	1

Trials

1 trial(s) available for rosiglitazone and Breast Cancer

Article	Year
Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1 Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors	2013

Article

Year

Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer.

Cancer chemotherapy and pharmacology, 2013, Volume: 71, Issue:1

Topics: Administration, Oral; Aged; Androstadienes; Antineoplastic Agents; Breast Neoplasms; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Humans; Metformin; Middle Aged; Obesity; Overweight; Postmenopause; Rosiglitazone; Thiazolidinediones; Time Factors

2013

Other Studies

34 other study(ies) available for rosiglitazone and Breast Cancer

Article	Year
CRISPR-Cas9 Genome-Wide Knockout Screen Identifies Mechanism of Selective Activity of Dehydrofalcarinol in Mesenchymal Stem-like Triple-Negative Breast Cancer Cells. Journal of natural products, 2020, 10-23, Volume: 83, Issue:10 Topics: 17-Hydroxysteroid Dehydrogenases; Aldehyde Oxidoreductases; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; CRISPR-Cas Systems; Female; Gene Knockout Techniques; Humans; Molecular Structure; Neoplastic Stem Cells; PPAR gamma; RNA, Small Interfering; Triple Negative Breast Neoplasms	2020
Loss of PPARγ activity characterizes early protumorigenic stromal reprogramming and dictates the therapeutic window of opportunity. Proceedings of the National Academy of Sciences of the United States of America, 2023, 10-17, Volume: 120, Issue:42 Topics: Adipocytes; Animals; Breast Neoplasms; Endothelial Cells; Female; Humans; Mice; PPAR gamma; Rosiglitazone	2023
Modulating Tumor-Associated Macrophage Polarization by Synthetic and Natural PPARγ Ligands as a Potential Target in Breast Cancer. Cells, 2020, 01-10, Volume: 9, Issue:1 Topics: Breast Neoplasms; Cell Differentiation; Cell Line; Cell Polarity; Culture Media, Conditioned; Cytokines; Docosahexaenoic Acids; Ethanolamines; Female; Humans; Ligands; Molecular Targeted Therapy; Monocytes; PPAR gamma; Rosiglitazone; Tumor-Associated Macrophages	2020
Beige adipocytes contribute to breast cancer progression. Oncology reports, 2021, Volume: 45, Issue:1 Topics: 3T3-L1 Cells; Adipocytes, Beige; Adipocytes, White; Animals; Breast Neoplasms; Cell Adhesion; Cell Differentiation; Cell Line, Tumor; Cell Movement; Culture Media, Conditioned; Disease Progression; Female; Humans; Mammary Glands, Animal; Mammary Neoplasms, Experimental; Mice; PPAR gamma; Rosiglitazone; Tumor Microenvironment	2021
Breast cancer-associated skeletal muscle mitochondrial dysfunction and lipid accumulation is reversed by PPARG. American journal of physiology. Cell physiology, 2021, 04-01, Volume: 320, Issue:4 Topics: Animals; Breast Neoplasms; Cachexia; Cell Line, Tumor; Culture Media, Conditioned; Female; HEK293 Cells; Humans; Lipid Metabolism; Mice; Mitochondria, Muscle; Myoblasts, Skeletal; Paracrine Communication; PPAR gamma; Rosiglitazone; Signal Transduction; Transcription, Genetic	2021
A Combined Self-Assembled Drug Delivery for Effective Anti-Breast Cancer Therapy. International journal of nanomedicine, 2021, Volume: 16 Topics: Animals; Body Weight; Breast Neoplasms; Cell Death; Cell Line, Tumor; Cell Movement; Dasatinib; Drug Carriers; Drug Delivery Systems; Drug Liberation; Endocytosis; Female; Hemolysis; Humans; Hyaluronic Acid; Mice, Inbred BALB C; Mice, Nude; Micelles; Nanoparticles; Particle Size; Proton Magnetic Resonance Spectroscopy; Rats, Sprague-Dawley; Rosiglitazone; Static Electricity; Tissue Distribution; Tumor Burden	2021
Gain Fat-Lose Metastasis: Converting Invasive Breast Cancer Cells into Adipocytes Inhibits Cancer Metastasis. Cancer cell, 2019, 01-14, Volume: 35, Issue:1 Topics: 3T3-L1 Cells; Adipocytes; Adipogenesis; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Transdifferentiation; Epithelial-Mesenchymal Transition; Female; Flavonoids; Humans; Mice; Neoplasm Metastasis; Neoplasm Transplantation; Proto-Oncogene Proteins c-met; Rosiglitazone; Signal Transduction; Transforming Growth Factor beta	2019
Increasing doxorubicin activity against breast cancer cells using PPARγ-ligands and by exploiting circadian rhythms. British journal of pharmacology, 2013, Volume: 169, Issue:5 Topics: Animals; Animals, Newborn; Antibiotics, Antineoplastic; Breast Neoplasms; Cell Cycle; Cells, Cultured; Collagen; Doxorubicin; Drug Chronotherapy; Female; Fibroblasts; Humans; Ligands; MCF-7 Cells; Melatonin; Myocytes, Cardiac; PPAR gamma; Rats; Rosiglitazone; Sarcomeres; Thiazolidinediones	2013
Targeting the ABCG2-overexpressing multidrug resistant (MDR) cancer cells by PPARγ agonists. British journal of pharmacology, 2013, Volume: 170, Issue:5 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzimidazoles; Benzoates; Biological Transport; Breast Neoplasms; Chlorophyll; Drug Resistance, Neoplasm; Endocytosis; Female; HEK293 Cells; Humans; Kinetics; MCF-7 Cells; Neoplasm Proteins; Phosphatidylinositol 3-Kinase; Pioglitazone; PPAR gamma; Protein Transport; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Rosiglitazone; Signal Transduction; Telmisartan; Thiazolidinediones; Transfection; Up-Regulation	2013
Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer. BMC genomics, 2013, Volume: 14 Suppl 5 Topics: Apoptosis; Breast Neoplasms; Caspase 8; Cell Line, Tumor; Coffee; Female; Gene Expression Regulation, Neoplastic; Humans; Hydroquinones; MCF-7 Cells; Membrane Potential, Mitochondrial; Models, Molecular; Molecular Docking Simulation; Phosphoglycerate Kinase; PPAR gamma; Reactive Oxygen Species; Rosiglitazone; Signal Transduction; Thiazolidinediones	2013
Involvement of insulin-like growth factor binding protein-3 in peroxisome proliferator-activated receptor gamma-mediated inhibition of breast cancer cell growth. Molecular and cellular endocrinology, 2015, Jan-05, Volume: 399 Topics: Breast Neoplasms; Cell Line, Tumor; Female; Gene Expression Regulation, Neoplastic; Humans; Hypoglycemic Agents; Insulin-Like Growth Factor Binding Protein 3; Mutation; Neoplasm Proteins; PPAR gamma; Rosiglitazone; Thiazolidinediones	2015
Role of cytochrome P450 2C83 (CYP2C83) in paclitaxel metabolism and paclitaxel-induced neurotoxicity. Pharmacogenomics, 2015, Volume: 16, Issue:9 Topics: Alleles; Amodiaquine; Antineoplastic Agents, Phytogenic; Aryl Hydrocarbon Hydroxylases; Breast Neoplasms; Cytochrome P-450 CYP2C8; Dose-Response Relationship, Drug; Female; HEK293 Cells; Humans; Isoenzymes; Neurotoxicity Syndromes; Ovarian Neoplasms; Paclitaxel; Polymorphism, Single Nucleotide; Risk Factors; Rosiglitazone; Substrate Specificity; Thiazolidinediones	2015
PPARγ Modulation of Cytokine-Stimulated MUC16 (CA125) Expression in Breast and Ovarian Cancer-Derived Cells. Journal of cellular biochemistry, 2017, Volume: 118, Issue:1 Topics: Anilides; Breast Neoplasms; CA-125 Antigen; Female; Gene Expression Regulation, Neoplastic; Humans; Interferon-gamma; MCF-7 Cells; Membrane Proteins; Neoplasm Proteins; Ovarian Neoplasms; PPAR gamma; Rosiglitazone; Thiazolidinediones; Tumor Necrosis Factor-alpha	2017
Rosiglitazone reduces breast cancer risk in Taiwanese female patients with type 2 diabetes mellitus. Oncotarget, 2017, Jan-10, Volume: 8, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Breast Neoplasms; Comorbidity; Diabetes Mellitus, Type 2; Drug Synergism; Female; Humans; Hypoglycemic Agents; Incidence; Middle Aged; Population Surveillance; Proportional Hazards Models; Risk; Rosiglitazone; Taiwan; Thiazolidinediones; Young Adult	2017
Differential potencies of naturally occurring regioisomers of nitrolinoleic acid in PPARgamma activation. Biochemistry, 2009, Jan-20, Volume: 48, Issue:2 Topics: Binding, Competitive; Breast Neoplasms; Cell Line, Tumor; Clone Cells; Dose-Response Relationship, Drug; Female; Genes, Reporter; Humans; Inhibitory Concentration 50; Linoleic Acids; Luciferases; Nitro Compounds; Nuclear Magnetic Resonance, Biomolecular; PPAR gamma; Radioligand Assay; Rosiglitazone; Stereoisomerism; Thiazolidinediones; Transcriptional Activation; Transduction, Genetic	2009
Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. The American journal of pathology, 2009, Volume: 175, Issue:3 Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; Breast; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; Epithelial Cells; Female; Humans; Ligands; NF-kappa B; PPAR gamma; Retinoid X Receptors; Rosiglitazone; Thiazolidinediones; Tretinoin; Tumor Suppressor Protein p53	2009
Repression of NHE1 expression by PPARgamma activation is a potential new approach for specific inhibition of the growth of tumor cells in vitro and in vivo. Cancer research, 2009, Nov-15, Volume: 69, Issue:22 Topics: Blotting, Western; Breast Neoplasms; Cation Transport Proteins; Cell Line, Tumor; Cell Proliferation; Diabetes Mellitus, Type 2; Female; Gene Expression; Gene Expression Regulation; Gene Silencing; Humans; Hypoglycemic Agents; Immunohistochemistry; PPAR gamma; Reverse Transcriptase Polymerase Chain Reaction; RNA, Small Interfering; Rosiglitazone; Sodium-Hydrogen Exchanger 1; Sodium-Hydrogen Exchangers; Thiazolidinediones; Transfection	2009
Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance. Breast cancer research and treatment, 2011, Volume: 129, Issue:3 Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cell Cycle; Cell Line, Tumor; Cells, Cultured; Chromans; Doxorubicin; Drug Resistance, Neoplasm; Epithelial Cells; Estrogen Receptor Modulators; Female; Heat-Shock Proteins; Humans; Mitochondria; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; PPAR gamma; Reactive Oxygen Species; Receptors, Estrogen; Rosiglitazone; Thiazolidinediones; Transcription Factors; Troglitazone	2011
Bid as a potential target of apoptotic effects exerted by low doses of PPARγ and RXR ligands in breast cancer cells. Cell cycle (Georgetown, Tex.), 2011, Jul-15, Volume: 10, Issue:14 Topics: Alitretinoin; Antineoplastic Agents; Apoptosis; BH3 Interacting Domain Death Agonist Protein; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Ligands; Mitochondria; PPAR gamma; Retinoid X Receptors; RNA Interference; RNA, Small Interfering; Rosiglitazone; Thiazolidinediones; Tretinoin; Tumor Suppressor Protein p53; Up-Regulation	2011
Integral role of PTP1B in adiponectin-mediated inhibition of oncogenic actions of leptin in breast carcinogenesis. Neoplasia (New York, N.Y.), 2013, Volume: 15, Issue:1 Topics: Adiponectin; Animals; Breast Neoplasms; Cell Line, Tumor; Cell Movement; Cell Transformation, Neoplastic; Down-Regulation; Extracellular Signal-Regulated MAP Kinases; Female; Humans; Leptin; MCF-7 Cells; Mice; Mice, Nude; Neoplasm Invasiveness; Phosphorylation; Protein Tyrosine Phosphatase, Non-Receptor Type 1; Proto-Oncogene Proteins c-akt; Rosiglitazone; Signal Transduction; Thiazolidinediones	2013
PPARgamma ligands and ATRA inhibit the invasion of human breast cancer cells in vitro. Breast cancer research and treatment, 2003, Volume: 79, Issue:1 Topics: Breast Neoplasms; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Nuclear Proteins; Pioglitazone; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazolidinediones; Tissue Inhibitor of Metalloproteinases; Transcription Factors; Tretinoin; Tumor Cells, Cultured	2003
Peroxisome proliferator-activated receptor-gamma upregulates caveolin-1 and caveolin-2 expression in human carcinoma cells. Oncogene, 2003, Jun-19, Volume: 22, Issue:25 Topics: Adenocarcinoma; Antigens, Differentiation; Antigens, Neoplasm; Breast Neoplasms; Caveolin 1; Caveolin 2; Caveolins; Cell Differentiation; Cell Line; Chromans; Colonic Neoplasms; Dimerization; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Gene Expression Regulation, Neoplastic; Genes, Dominant; Humans; Kidney; Ligands; Macromolecular Substances; Membrane Microdomains; Neoplasm Proteins; Phenotype; Phenylacetates; Prostaglandin D2; Protein Structure, Tertiary; Receptors, Cytoplasmic and Nuclear; RNA, Messenger; RNA, Neoplasm; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone; Tumor Cells, Cultured	2003
Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Molecular and cellular biology, 2003, Volume: 23, Issue:17 Topics: 3T3 Cells; Animals; Breast; Breast Neoplasms; CCAAT-Enhancer-Binding Protein-alpha; CCAAT-Enhancer-Binding Protein-beta; Cyclin D1; Ecdysterone; Epithelial Cells; Fatty Liver; Female; Gene Expression Regulation; Humans; Mice; Mice, Mutant Strains; Mice, Transgenic; Models, Molecular; Mutation; Protein Conformation; Receptors, Cytoplasmic and Nuclear; Reference Values; Repressor Proteins; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors; Transcriptional Activation	2003
Enhancement of BRCA1 gene expression by the peroxisome proliferator-activated receptor gamma in the MCF-7 breast cancer cell line. Oncogene, 2003, Aug-21, Volume: 22, Issue:35 Topics: BRCA1 Protein; Breast Neoplasms; Female; Genetic Predisposition to Disease; Humans; Receptors, Cytoplasmic and Nuclear; Rosiglitazone; Thiazoles; Thiazolidinediones; Transcription Factors	2003
GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation. British journal of pharmacology, 2004, Volume: 143, Issue:8 Topics: Anilides; Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Cell Survival; Dose-Response Relationship, Drug; Drug Synergism; Humans; PPAR gamma; Rosiglitazone; Thiazolidinediones	2004
Selective activation of PPARgamma in breast, colon, and lung cancer cell lines. Molecular and cellular endocrinology, 2005, May-12, Volume: 235, Issue:1-2 Topics: Alitretinoin; Anilides; Breast Neoplasms; Caco-2 Cells; Cell Line, Tumor; Colonic Neoplasms; Female; Gene Expression Regulation, Neoplastic; Genes, Reporter; HT29 Cells; Humans; Ligands; Lung Neoplasms; PPAR gamma; Prostaglandin D2; Retinoid X Receptor alpha; RNA, Messenger; Rosiglitazone; Thiazolidinediones; Transfection; Tretinoin	2005
Estrogen receptor alpha binds to peroxisome proliferator-activated receptor response element and negatively interferes with peroxisome proliferator-activated receptor gamma signaling in breast cancer cells. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005, Sep-01, Volume: 11, Issue:17 Topics: Breast Neoplasms; Cell Proliferation; Chromatin Immunoprecipitation; Electrophoretic Mobility Shift Assay; Estradiol; Estrogen Receptor alpha; HeLa Cells; Humans; Ligands; Phosphatidylinositol 3-Kinases; Phosphoric Monoester Hydrolases; Phosphorylation; PPAR gamma; Promoter Regions, Genetic; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Signal Transduction; Thiazolidinediones; Thymidine; Transcription, Genetic; Transcriptional Activation; Tumor Suppressor Proteins; Vasodilator Agents	2005
Increased PTEN expression due to transcriptional activation of PPARgamma by Lovastatin and Rosiglitazone. International journal of cancer, 2006, May-15, Volume: 118, Issue:10 Topics: Antineoplastic Agents; Breast Neoplasms; Cell Line, Tumor; Dose-Response Relationship, Drug; G1 Phase; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Hypoglycemic Agents; Lovastatin; PPAR gamma; PTEN Phosphohydrolase; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Up-Regulation	2006
Differential anti-proliferative actions of peroxisome proliferator-activated receptor-gamma agonists in MCF-7 breast cancer cells. Biochemical pharmacology, 2006, Aug-28, Volume: 72, Issue:5 Topics: Apoptosis; Base Sequence; Breast Neoplasms; Cell Line, Tumor; DNA Fragmentation; DNA Primers; Humans; Indenes; Morpholines; Phosphorylation; PPAR gamma; Proto-Oncogene Proteins c-akt; PTEN Phosphohydrolase; RNA Interference; Rosiglitazone; Thiazolidinediones	2006
Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. Molecular endocrinology (Baltimore, Md.), 2006, Volume: 20, Issue:12 Topics: Base Pairing; Breast Neoplasms; Caspase 9; Cell Cycle; Cell Line, Tumor; Chromatin Immunoprecipitation; DNA Fragmentation; G1 Phase; Genes, p53; Humans; NF-kappa B; PPAR gamma; Promoter Regions, Genetic; Resting Phase, Cell Cycle; Rosiglitazone; Thiazolidinediones; Tumor Suppressor Protein p53	2006
Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2007, Jan-01, Volume: 13, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Cell Proliferation; Disease Progression; Female; Humans; Hypoglycemic Agents; Ki-67 Antigen; Middle Aged; Pilot Projects; PPAR gamma; Rosiglitazone; Signal Transduction; Thiazolidinediones	2007
Transactivation of ERalpha by Rosiglitazone induces proliferation in breast cancer cells. Breast cancer research and treatment, 2008, Volume: 108, Issue:1 Topics: Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Estrogen Receptor alpha; Female; Humans; Hypoglycemic Agents; Male; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Rosiglitazone; Thiazolidinediones; Transcriptional Activation	2008
Rosiglitazone sensitizes MDA-MB-231 breast cancer cells to anti-tumour effects of tumour necrosis factor-alpha, CH11 and CYC202. Endocrine-related cancer, 2007, Volume: 14, Issue:2 Topics: Antineoplastic Combined Chemotherapy Protocols; Blotting, Western; Breast Neoplasms; Cell Line, Tumor; Chalcones; DNA Replication; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression; Humans; PPAR gamma; Purines; Response Elements; Reverse Transcriptase Polymerase Chain Reaction; Roscovitine; Rosiglitazone; Thiazolidinediones; Transcriptional Activation; Tumor Necrosis Factor-alpha	2007
Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. Cancer research, 2000, Mar-15, Volume: 60, Issue:6 Topics: Adipose Tissue; Animals; Aromatase; Aromatase Inhibitors; Binding, Competitive; Breast; Breast Neoplasms; Cell Line; Cells, Cultured; Chromans; Dose-Response Relationship, Drug; Estrogens; Female; Gene Expression Regulation, Enzymologic; Humans; Ligands; Promoter Regions, Genetic; Prostaglandin D2; Receptors, Cytoplasmic and Nuclear; Recombinant Fusion Proteins; Rosiglitazone; Stromal Cells; Thiazoles; Thiazolidinediones; Transcription Factors; Transcription, Genetic; Troglitazone	2000